NO20004025L - Anvendelse av negative reguleringselementer for den neurospesifikke ekspresjon av transgener - Google Patents

Anvendelse av negative reguleringselementer for den neurospesifikke ekspresjon av transgener

Info

Publication number
NO20004025L
NO20004025L NO20004025A NO20004025A NO20004025L NO 20004025 L NO20004025 L NO 20004025L NO 20004025 A NO20004025 A NO 20004025A NO 20004025 A NO20004025 A NO 20004025A NO 20004025 L NO20004025 L NO 20004025L
Authority
NO
Norway
Prior art keywords
transgenes
regulatory elements
negative regulatory
neurospecific
expression
Prior art date
Application number
NO20004025A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004025D0 (no
Inventor
Helene Kiefer
Jacques Mallet
Stephanie Millecamps
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20004025D0 publication Critical patent/NO20004025D0/no
Publication of NO20004025L publication Critical patent/NO20004025L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/32—Vector systems having a special element relevant for transcription being an silencer not forming part of the promoter region

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20004025A 1998-02-12 2000-08-10 Anvendelse av negative reguleringselementer for den neurospesifikke ekspresjon av transgener NO20004025L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9801715A FR2774698B1 (fr) 1998-02-12 1998-02-12 Utilisation d'elements de regulation negative pour l'expression neurospecifique de transgenes
PCT/FR1999/000061 WO1999041396A1 (fr) 1998-02-12 1999-01-14 Utilisation d'elements de regulation negative pour l'expression neurospecifique de transgenes

Publications (2)

Publication Number Publication Date
NO20004025D0 NO20004025D0 (no) 2000-08-10
NO20004025L true NO20004025L (no) 2000-10-10

Family

ID=9522917

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004025A NO20004025L (no) 1998-02-12 2000-08-10 Anvendelse av negative reguleringselementer for den neurospesifikke ekspresjon av transgener

Country Status (16)

Country Link
US (1) US20060121013A1 (cs)
EP (2) EP1120466A3 (cs)
JP (1) JP2002503476A (cs)
KR (2) KR100720201B1 (cs)
CN (1) CN1221665C (cs)
AU (1) AU766153B2 (cs)
BR (1) BR9907759A (cs)
CA (1) CA2321220A1 (cs)
CZ (1) CZ299915B6 (cs)
FR (1) FR2774698B1 (cs)
HU (1) HUP0100660A3 (cs)
IL (1) IL137609A0 (cs)
NO (1) NO20004025L (cs)
PL (1) PL198201B1 (cs)
WO (1) WO1999041396A1 (cs)
ZA (1) ZA991070B (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120754249A (zh) * 2021-09-30 2025-10-10 上海鲸奇生物科技有限公司 直接转分化治疗神经系统疾病

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912411A (en) * 1993-06-14 1999-06-15 University Of Heidelberg Mice transgenic for a tetracycline-inducible transcriptional activator
US5763217A (en) * 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
US5935811A (en) * 1995-03-03 1999-08-10 California Institute Of Technology Neuron-restrictive silencer factor nucleic acids
TWM447817U (zh) * 2012-09-21 2013-03-01 Basso Ind Corp 具有縮頭部的氣動棘輪扳手
TWI555260B (zh) * 2016-02-05 2016-10-21 見智科技股份有限公司 電池模組及其製造方法

Also Published As

Publication number Publication date
CZ299915B6 (cs) 2008-12-29
KR20010072544A (ko) 2001-07-31
AU766153B2 (en) 2003-10-09
JP2002503476A (ja) 2002-02-05
FR2774698B1 (fr) 2002-03-01
HUP0100660A1 (hu) 2001-06-28
KR100720201B1 (ko) 2007-05-21
IL137609A0 (en) 2001-07-24
US20060121013A1 (en) 2006-06-08
WO1999041396A1 (fr) 1999-08-19
HUP0100660A3 (en) 2003-10-28
BR9907759A (pt) 2000-10-17
CA2321220A1 (fr) 1999-08-19
NO20004025D0 (no) 2000-08-10
CN1290303A (zh) 2001-04-04
PL342265A1 (en) 2001-06-04
CZ20002906A3 (cs) 2000-11-15
EP1120466A3 (fr) 2003-01-22
EP1120466A2 (fr) 2001-08-01
PL198201B1 (pl) 2008-06-30
EP1053341A1 (fr) 2000-11-22
ZA991070B (en) 1999-08-11
FR2774698A1 (fr) 1999-08-13
CN1221665C (zh) 2005-10-05
AU2058199A (en) 1999-08-30
KR20070013362A (ko) 2007-01-30

Similar Documents

Publication Publication Date Title
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DK0965343T3 (da) Ziprasidonformuleringer
PT1109558E (pt) Formulacoes de ranolazina de libertacao controlada
ID24372A (id) SENYAWA-SENYAWA 4-AMINO-TIAZOL-2-IL SEBAGAI PENGHAMBAT-PENGHAMBAT CDKs
NO20005488D0 (no) Hematopoetisk stimulering
DK0951447T3 (da) Vandbehandling
DE69902223D1 (de) Polyfunktionelle organosilan behandlung von kieselsäure
DE69934510D1 (de) Verminderung des haarwuchses
DE69720301D1 (de) Herstellung von Silanen
EP0781326A4 (en) THE IRS GENFAMILY
DE69715054D1 (de) Herstellung von Silanen
DE69813402D1 (de) Herstellung von Alkylhalogensilanen
PT1100329E (pt) Composicoes aquosas reguladoras do crescimento
DE59707035D1 (de) Reversionsarme Vernetzer
NO20004025D0 (no) Anvendelse av negative reguleringselementer for den neurospesifikke ekspresjon av transgener
DE69816358D1 (de) Herstellung von Alkylhalosilanen
ID20397A (id) Pemurnian kompleks transkripsi tingkat lebih tinggi dari hewan bukan manusia transgenik
IT1277115B1 (it) Hals-fosforammidi come agenti stabilizzanti
ITMI950746A0 (it) Hals-fosfoniti come agenti stabilizzanti
ID24439A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
ATE253366T1 (de) Verwendung von 7-apha-methyl-17-alpha-ethynyl- estrane derivaten zur behandlung von atherosclerose
ATA208398A (de) Handstück
KR970050593U (ko) 수족관
FI102961B1 (fi) Menetelmä tuhkan käsittelemiseksi
NO996166L (no) FremgangsmÕte for behandling av avluter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application